NDA 203340 · Azurity
Nymalize
Nimodipine · Oral · Dihydropyridine Calcium Channel Blocker
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Aug 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
May 10, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
5 Phase 3, 3 recruiting
FAERS reports
1,122
980 serious, 115 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 30, 2024.
NYMALIZE is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). NYMALIZE is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). ( 1 )
Mechanism: Nimodipine is a dihydropyridine calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood-brain barrier; concentrations of nimodipine as high as 12.5 ng/mL have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 10, 2013 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewLabelSummary Review
2 products under this application
- NYMALIZE · NIMODIPINE 3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
- NYMALIZE · NIMODIPINE 6MG/ML · SOLUTION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nimodipine" as an intervention, any sponsor and status, largest first.
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe PreeclampsiaPivotal-lookingCompleted
FDA Office of Orphan Products DevelopmentFederal agency
NCT00004399 · 2,000 participants · Start Sep 1995
Drug: magnesium sulfate; nimodipine · For: Pre-eclampsia
- Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide PoisoningPivotal-lookingCompleted
University of EdinburghAcademic, hospital or other
NCT03925025 · 1,728 participants · Start Jun 11, 2020 · Primary completion Mar 31, 2025
Drug: Magnesium Sulfate; Nimodipine · For: Anticholinesterase Insecticide Poisoning; Pesticide Poisoning
Sites: Rajshahi, Bangladesh; Bogura, Bangladesh; Chittagong, Bangladesh · 7 sites in all
- Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic StrokesPivotal-lookingStatus unknown
Ministry of Science and Technology of the People´s Republic of ChinaGovernment (non-federal)
NCT01220622 · 656 participants (planned) · Start Oct 2010 · Primary completion Apr 2012
Drug: Nimodipine; Placebo · For: Stroke; Mild Cognitive Impairment
Sites: Beijing, China
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid HemorrhagePivotal-lookingNot yet recruiting
Centre Hospitalier St AnneAcademic, hospital or other
NCT07144956 · 630 participants (planned) · Start Dec 15, 2025 · Primary completion Dec 14, 2029
Drug: Cilostazol (Pletal®) 100 mg Tablets; Placebo and 1 more · For: Aneurysmal Subarachnoid Hemorrhage
- Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid HemorrhagePivotal-lookingTerminated
Edge Therapeutics IncIndustry
NCT02790632 · 374 participants (planned) · Start Jul 2016 · Primary completion Jun 2018
Drug: EG-1962 (nimodipine microparticles); Enteral Nimodipine · For: Subarachnoid Hemorrhage, Aneurysmal
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 79 sites in all
- Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAHPivotal-lookingActive, not recruiting
Grace Therapeutics Inc.Industry
NCT05995405 · 100 participants (planned) · Start Oct 20, 2023 · Primary completion Dec 2024
Drug: GTX-104; Nimotop 30 MG Oral Capsule · For: Aneurysmal Subarachnoid Hemorrhage (aSAH)
Sites: Birmingham, Alabama; Phoenix, Arizona; Fresno, California · 22 sites in all
Edge Therapeutics IncIndustry
NCT01893190 · 73 participants · Start Sep 2013 · Primary completion Jan 2016
Drug: Nimodipine; Nimodipine Microparticles · For: Ruptured Cerebral Aneurysm; Ruptured Berry Aneurysm
Sites: Phoenix, Arizona; Los Angeles, California; Chicago, Illinois · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective89
- off label use72
- hypotension59
- subarachnoid haemorrhage43
- toxicity to various agents34
- diarrhoea33
- dizziness33
- headache33
- drug interaction32
- renal failure31
- reversible cerebral vasoconstriction syndrome31
- condition aggravated29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 4 |
| 2006 | 13 |
| 2007 | 15 |
| 2008 | 28 |
| 2009 | 29 |
| 2010 | 41 |
| 2011 | 40 |
| 2012 | 40 |
| 2013 | 36 |
| 2014 | 54 |
| 2015 | 55 |
| 2016 | 43 |
| 2017 | 47 |
| 2018 | 79 |
| 2019 | 68 |
| 2020 | 94 |
| 2021 | 81 |
| 2022 | 65 |
| 2023 | 85 |
| 2024 | 69 |
| 2025 | 78 |
| 2026 | 43 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.
Polito NB, Fellows SE · J Emerg Med 2017 · Systematic Review
- Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review.
Song TJ, Lee KH, Li H, et al. · Eur Rev Med Pharmacol Sci 2021 · Systematic Review
- Nimodipine improves vocal fold and facial motion recovery after injury: A systematic review and meta-analysis.
Lin RJ, Klein-Fedyshin M, Rosen CA · Laryngoscope 2019 · Meta-Analysis, Systematic Review
- Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.
Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. · Cochrane Database Syst Rev 2010 · Meta-Analysis, Systematic Review
- Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.
Allen GS, Ahn HS, Preziosi TJ, et al. · N Engl J Med 1983 · Clinical Trial, Randomized Controlled Trial
- Nimodipine Pharmacokinetic Variability in Various Patient Populations.
Mahmoud SH, Ji X, Isse FA · Drugs R D 2020 · Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.